SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients

Date

2018

Author

Merat, S

Poustchi, H

Sharifi, AH

Nateghi, A

Hajiani, E

Gharavi, A

Somi, MH

Ghadir, MR

Kalantari, H

Mansour-Ghanaei, F

Karimi, J

Fattahi, MR

Baniasadi, N

Moosavy, S

Dehghan-Manshadi, SA

Sofian, M

Sayad, B

Abazar, P

Amiriani, T

Bakhshipour, A

Mokhtare, M

Sharifian, A

Minakari, M

Zahedi, MJ

Sohrabi, M

Ghezloo, M

Jamali, R

Toosi, SMV

Afshar, B

Maleki, I

Ziaee, M

Hormati, A

Samani, FR

Eslami, L

Fakheri, H

Goshayeshi, L

Sali, S

Sohrabpour, AA

Norouzi, A

Sardarian, H

Janbakhsh, A

Shayesteh, AA

Ahmadi, L

Merat, D

Shayesteh, E

Malekzadeh, R

Metadata

Show full item record

URI

http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44274

Collections

• Published Articles